cheng deng

Prof. cheng deng


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CDcheng deng
cheng deng
HCHaidi Chen
Haidi Chen
NYNa Yang
Na Yang
YFYi Feng
Yi Feng
AHAaron J. W. Hsueh
Aaron J. W. Hsueh
Apela (APJ early endogenous ligand, also known as elabela or toddler) is a recently discovered peptide hormone. Based on genetic studies in zebrafish, apela was found to be important for endoderm differentiation and heart development during embryogenesis. Although common phenotypes of apela and APJ null zebrafish during embryonic development suggested that apela interacts with the APJ receptor, kinetics of apela binding to APJ and intracellular signaling pathways for apela remain unknown. The role of apela in adults is also uncertain. Using a chimeric apela ligand, we showed direct binding of apela to APJ with high affinity (Kd=0.51nM) and the ability of apelin, the known peptide ligand for APJ, to compete for apela binding. Apela, similar to apelin, acts through the inhibitory G protein pathway by inhibiting forskolin-stimulated cAMP production and by inducing ERK1/2 phosphorylation. In adult rats, apela is expressed exclusively in the kidney, unlike the wide tissue distribution of apelin. In vivo studies demonstrated the ability of apela to regulate fluid homeostasis by increasing diuresis and water intake. Dose-response studies further indicated that apela induces 2- and 5-fold higher maximal responses than apelin ERK1/2 phosphorylation and diuresis/water intake, respectively. After designing an apela antagonist, we further demonstrated the role of endogenous ligand(s) in regulating APJ-mediated fluid homeostasis. Our results identified apela as a potent peptide hormone capable of regulating fluid homeostasis in adult kidney through coupling to the APJ-mediated Gi signaling pathway.

2 January 2025 in Cell
Verified
Journal Article
Closed access
XWXin Wen
Xin Wen
PSPan Shang
Pan Shang
HCHaidi Chen
Haidi Chen
LGLulu Guo
Lulu Guo
NRNaikang Rong
Naikang Rong
JSJinpeng Sun
Jinpeng Sun

20 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
HZHuaping Zheng
Huaping Zheng
JYJingjing Yu
Jingjing Yu
LGLuhua Gao
Luhua Gao
KWKexin Wang
Kexin Wang
ZXZheng Xu
Zheng Xu
CDcheng deng
cheng deng
G protein-coupled sphingosine-1-phosphate receptor 1 (S1PR1), a drug target for inflammatory bowel disease (IBD), enables immune cells to egress from lymph nodes, but the treatment increases the risk of immunosuppression. The functional signaling pathway triggered by S1PR1 activation in endothelial cells and its therapeutic application remains unclear. Here, we showed that S1PR1 is highly expressed in endothelial cells of IBD patients and positively correlated with endothelial markers. Gi-biased agonist-SAR247799 activated S1PR1 and reversed pathology in male mouse and organoid IBD models by protecting the integrity of the endothelial barrier without affecting immune cell egress. Cryo-electron microscopy structure of S1PR1-Gi signaling complex bound to SAR247799 with a resolution of 3.47 Å revealed the recognition mode for the biased ligand. With the efficacy of SAR247799 in treating other endothelial dysfunction-associated inflammatory diseases, our study offers mechanistic insights into the Gi-biased S1PR1 agonist and represents a strategy for endothelial dysfunction-associated disease treatment.

23 January 2026 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
CCChunmei Cai
Chunmei Cai
GNGuohua Ni
Guohua Ni
LCLei Chen
Lei Chen
CDcheng deng
cheng deng
SCShengjun Chai
Shengjun Chai
RGRi-li Ge
Ri-li Ge
At high altitudes, which typically exceed 2500 m, approximately 80 million people reside permanently, with over a million visitors annually. The primary effect of high altitude is hypobaric hypoxia, which leads to decreased oxygen availability and a cascade of physiological responses. However, inadequate or excessive responses can lead to malacclimatization, resulting in hypoxemia and various high-altitude illnesses, including acute mountain sickness (AMS), high-altitude cerebral edema (HACE), high-altitude pulmonary edema (HAPE), chronic mountain sickness (CMS), and high-altitude pulmonary hypertension (HAPH). Acute altitude illnesses (AMS, HACE, and HAPE) stem from inadequate acclimatization, whereas chronic conditions (CMS and HAPH) reflect prolonged or excessive adaptive responses. This review briefly summarizes the current knowledge on the clinical manifestations, epidemiology, and risk factors for high-altitude diseases. Additionally, this review systematically discusses the most recent pathophysiological mechanisms underlying these conditions, with a special emphasis on genetic susceptibility and chronic altitude illness (CMS and HAPH). Furthermore, a comprehensive overview of current prevention and treatment strategies is provided, emphasizing the promising effects of natural medicines, especially traditional Tibetan medicines. Despite extensive research, the exact mechanisms underlying these illnesses remain elusive, and options for their management are still limited. This review aims to provide novel insights into the pathogenic mechanisms of these complex conditions and guide future research directions to improve the prevention and management of high-altitude illnesses.

6 March 2019 in PLOS Biology
Verified
Journal Article
Open access
PDF file
HTHuihao Tang
Huihao Tang
CSChuanjun Shu
Chuanjun Shu
HCHaidi Chen
Haidi Chen
XZXiaojing Zhang
Xiaojing Zhang
ZZZhuqing Zang
Zhuqing Zang
CDcheng deng
cheng deng
G protein–coupled receptors (GPCRs) play an important role in physiology and disease and represent the most productive drug targets. Orphan GPCRs, with their endogenous ligands unknown, were considered a source of drug targets and consequently attract great interest to identify their endogenous cognate ligands for deorphanization. However, a contrary view to the ubiquitous existence of endogenous ligands for every GPCR is that there might be a significant overlooked fraction of orphan GPCRs that function constitutively in a ligand-independent manner only. Here, we investigated the evolution of the bombesin receptor–ligand family in vertebrates in which one member—bombesin receptor subtype-3 (BRS3)—is a potential orphan GPCR. With analysis of 17 vertebrate BRS3 structures and 10 vertebrate BRS3 functional data, our results demonstrated that nonplacental vertebrate BRS3 still connects to the original ligands—neuromedin B (NMB) and gastrin-releasing peptide (GRP)—because of adaptive evolution, with significantly changed protein structure, especially in three altered key residues (Q127R, P205S, and R294H) originally involved in ligand binding/activation, whereas the placental mammalian BRS3 lost the binding affinity to NMB/GRP and constitutively activates Gs/Gq/G12 signaling in a ligand-independent manner. Moreover, the N terminus of placental mammalian BRS3 underwent positive selection, exhibiting significant structural differences compared to nonplacental vertebrate BRS3, and this domain plays an important role in constitutive activity of placental mammalian BRS3. In conclusion, constitutively active BRS3 is a genuinely orphan GPCR in placental mammals, including human. To our knowledge, this study identified the first example that might represent a new group of genuinely orphan GPCRs that will never be deorphanized by the discovery of a natural ligand and provided new perspectives in addition to the current ligand-driven GPCR deorphanization. The current model on G protein–coupled receptors (GPCRs) is that they have at least one endogenous ligand for the activation of the heterotrimeric G proteins that controls lots of physiological functions. Currently, 140 out of approximately 800 GPCRs are referred to as orphan because of a lack of knowledge about their endogenous ligands, and they attract great interest in major medical institutes and pharmaceutical companies. Can a “ligand-receptor” model apply to all the GPCRs? Our study shows that it probably cannot. By studying the evolution of a classic orphan GPCR–bombesin receptor subtype-3 (BRS3), we show that placental mammalian BRS3 is constitutively active, in contrast to nonplacental vertebrate BRS3, which actually connects to its original ligands—neuromedin B (NMB) and gastrin-releasing peptide (GRP). Protein structure analysis and experiment data also suggest that placental mammalian BRS3, including human BRS3, lost connection with its original ligands during placental mammalian evolution. Therefore, we propose a new point of view that a considerable number of orphan GPCRs do not have endogenous ligands and might represent a new group of GPCRs that are genuinely orphan GPCRs and will never be deorphanized by discovery of a natural ligand. This new finding will provide new perspectives in current ligand-driven GPCR deorphanization.

23 September 2022 in Pharmacological Research
Verified
Journal Article
Closed access
KZKe Zhang
Ke Zhang
YGYan-Chen Guo
Yan-Chen Guo
XWXiao-Dong Wang
Xiao-Dong Wang
YZYing-Jie Zhu
Ying-Jie Zhu
BPBing-Xing Pan
Bing-Xing Pan
Ti-fei YuanTi-fei Yuan
Ti-fei Yuan